Elena Garralda

10.1k total citations · 4 hit papers
210 papers, 3.3k citations indexed

About

Elena Garralda is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Elena Garralda has authored 210 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Oncology, 53 papers in Radiology, Nuclear Medicine and Imaging and 44 papers in Immunology. Recurrent topics in Elena Garralda's work include Cancer Immunotherapy and Biomarkers (73 papers), CAR-T cell therapy research (42 papers) and Cancer Genomics and Diagnostics (31 papers). Elena Garralda is often cited by papers focused on Cancer Immunotherapy and Biomarkers (73 papers), CAR-T cell therapy research (42 papers) and Cancer Genomics and Diagnostics (31 papers). Elena Garralda collaborates with scholars based in Spain, United States and Germany. Elena Garralda's co-authors include Carlos Gómez-Martín, Bruno Sangro, Ignacio Melero, Jesús Prìeto, Pablo Sarobe, Manuel de la Mata, Esther Larrea, José Ignacio Riezu‐Boj, Pilar Barrera and José Luis Perez‐Gracia and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Elena Garralda

190 papers receiving 3.2k citations

Hit Papers

A clinical trial of CTLA-... 2013 2026 2017 2021 2013 2022 2022 2024 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
    2013 764 citations Elena Garralda, Ignacio Melero et al. profile →
  2. Delivering precision oncology to patients with cancer
    2022 197 citations Joaquı́n Mateo, Lotte Steuten et al. Nature Medicine profile →
  3. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
    2022 144 citations Elena Garralda, Martin Schüler et al. Nature Medicine profile →
  4. Bispecific antibodies: advancing precision oncology
    2024 53 citations Elena Garralda et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Elena Garralda 1.7k 679 674 650 561 210 3.3k
John H. Strickler 2.1k 1.3× 399 0.6× 941 1.4× 962 1.5× 305 0.5× 216 3.4k
Cinzia Orlandini 2.2k 1.3× 202 0.3× 622 0.9× 877 1.3× 478 0.9× 74 3.7k
Vincent Chung 2.3k 1.4× 520 0.8× 897 1.3× 631 1.0× 112 0.2× 169 3.6k
Anne M. Noonan 1.3k 0.8× 354 0.5× 561 0.8× 396 0.6× 185 0.3× 117 2.1k
Erika Martinelli 2.2k 1.3× 202 0.3× 629 0.9× 859 1.3× 497 0.9× 86 3.4k
Nancy Lewis 1.5k 0.9× 516 0.8× 875 1.3× 811 1.2× 124 0.2× 62 2.9k
Desmond Yip 1.6k 1.0× 145 0.2× 579 0.9× 938 1.4× 321 0.6× 162 2.9k
Richard J. Epstein 1.3k 0.8× 159 0.2× 1.3k 2.0× 735 1.1× 265 0.5× 129 3.3k
Ira Wollner 2.6k 1.6× 1.4k 2.0× 486 0.7× 739 1.1× 238 0.4× 31 3.4k
Petronella O. Witteveen 2.0k 1.2× 244 0.4× 807 1.2× 799 1.2× 89 0.2× 95 3.8k

Countries citing papers authored by Elena Garralda

Since Specialization
Citations

This map shows the geographic impact of Elena Garralda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Garralda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Garralda more than expected).

Fields of papers citing papers by Elena Garralda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elena Garralda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Garralda. The network helps show where Elena Garralda may publish in the future.

Co-authorship network of co-authors of Elena Garralda

This figure shows the co-authorship network connecting the top 25 collaborators of Elena Garralda. A scholar is included among the top collaborators of Elena Garralda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Garralda. Elena Garralda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Viaplana, Cristina, Joaquı́n Mateo, Francesc Salvà, et al.. (2025). A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer. Cell Reports Medicine. 6(4). 102032–102032. 3 indexed citations
2.
3.
Toledo, Rodrigo A., Oriol Mirallas, Ana Carolina Ramos Moreno, et al.. (2024). Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials.. Journal of Clinical Oncology. 42(16_suppl). 2510–2510. 2 indexed citations
4.
Melero, Ignacio, Maria J. de Miguel, Guillermo de Velasco, et al.. (2024). Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancer.. Journal of Clinical Oncology. 42(16_suppl). 2513–2513. 2 indexed citations
5.
6.
El-Khoueiry, Anthony B., Elena Garralda, Andrés Cervantes, et al.. (2024). A phase I monotherapy dose escalation study of HFB301001, a novel next generation OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2531–2531. 1 indexed citations
7.
Villalona‐Calero, Miguel A., et al.. (2024). A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 3125–3125. 4 indexed citations
8.
Navarro, Vı́ctor, Marta Ligero, Alonso García-Ruiz, et al.. (2024). Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer. Radiology Artificial Intelligence. 6(2). e230118–e230118. 15 indexed citations
9.
Curigliano, Giuseppe, M.M. Jimenez, Tomokazu Shimizu, et al.. (2024). A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies. ESMO Open. 9(8). 103643–103643. 7 indexed citations
10.
Calvo, Emiliano, Elena Garralda, Guzmán Alonso, et al.. (2023). 1030P Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors. Annals of Oncology. 34. S626–S626. 7 indexed citations
11.
Pascual, Tomás, Blanca González‐Farré, Fara Brasó‐Maristany, et al.. (2023). 2239P Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types. Annals of Oncology. 34. S1153–S1154. 1 indexed citations
12.
Garralda, Elena, Do Youn Oh, Antoîne Italiano, et al.. (2023). Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103). The Journal of Clinical Pharmacology. 64(5). 544–554. 9 indexed citations
13.
Ligero, Marta, Garazi Serna, Omar S. M. El Nahhas, et al.. (2023). Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression. Cancer Research Communications. 4(1). 92–102. 13 indexed citations
14.
Tabernero, Josep, Eric Van Cutsem, Elena Garralda, et al.. (2023). A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAFV600E-MutantKRASWild-Type Metastatic Colorectal Cancer. The Oncologist. 28(3). 230–238. 34 indexed citations
15.
Mateo, Joaquı́n, Lotte Steuten, Philippe Aftimos, et al.. (2022). Delivering precision oncology to patients with cancer. Nature Medicine. 28(4). 658–665. 197 indexed citations breakdown →
16.
Boni, Valentina, Alexander Drilon, John F. Deeken, et al.. (2021). SO-29 Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: An expanded dataset. Annals of Oncology. 32. S214–S215. 10 indexed citations
17.
Garralda, Elena, Ravit Geva, Eytan Ben‐Ami, et al.. (2020). 412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors. SHILAP Revista de lepidopterología. A250.2–A251. 6 indexed citations
18.
Atrafi, Florence, Harry J.M. Groen, Lauren A. Byers, et al.. (2018). A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Clinical Cancer Research. 25(2). 496–505. 38 indexed citations
19.
Garralda, Elena, Keren Paz, Pedro P. López‐Casas, et al.. (2014). Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. Clinical Cancer Research. 20(9). 2476–2484. 107 indexed citations
20.
Garralda, Elena. (2002). Anxiety disorders in children and adolescents. Research, assessment and intervention. Journal of Neurology Neurosurgery & Psychiatry. 72(4). 556–556.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John H. Strickler Breakdown of academic impact, for papers by Cinzia Orlandini Breakdown of academic impact, for papers by Vincent Chung Breakdown of academic impact, for papers by Anne M. Noonan Breakdown of academic impact, for papers by Erika Martinelli Breakdown of academic impact, for papers by Nancy Lewis Breakdown of academic impact, for papers by Desmond Yip Breakdown of academic impact, for papers by Richard J. Epstein Breakdown of academic impact, for papers by Ira Wollner Breakdown of academic impact, for papers by Petronella O. Witteveen
Rankless by CCL
2026